Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 4/2020

01-04-2020 | Original Article

Comorbidities, treatment-related consequences, and health-related quality of life among rural cancer survivors

Authors: Shaila M. Strayhorn, Leslie R. Carnahan, Kristine Zimmermann, Theresa A. Hastert, Karriem S. Watson, Carol Estwing Ferrans, Yamilé Molina

Published in: Supportive Care in Cancer | Issue 4/2020

Login to get access

Abstract

Purpose

We explored how lifetime comorbidities and treatment-related cancer symptoms were associated with quality of life (QOL) in rural cancer survivors.

Methods

Survivors (n = 125) who were rural Illinois residents aged 18+ years old were recruited from January 2017 to September 2018. We conducted 4 multivariable regressions with QOL domains as outcomes (social well-being, functional well-being, mental health—MHQOL, physical health—PHQOL); the number of physical and psychological comorbidities (e.g., arthritis, high blood pressure, stroke) and treatment-related cancer symptoms (e.g., worrying, feeling sad, lack of appetite, lack of energy) as predictors; and, cancer-related and demographic factors related to these variables as covariates.

Results

The number of comorbidities and number of treatment-related symptoms were inversely associated with functional well-being (Std β = − 0.36, p < 0.0001 and − 0.18, p = 0.03), and MHQOL (Std β = − 0.30, p = 0.001 and Std β = − 0.25, p = 0.004). Comorbidities were associated inversely with social well-being (Std β = − 0.27, p = .003). Comorbidities and treatment-related symptoms were not associated with PHQOL (p = 0.20–0.24). Sensitivity analyses suggested that psychological comorbidities, treatment-related psychological symptoms, and physical comorbidities were associated with social well-being, functional well-being, and MHQOL.

Conclusions

Our study highlights the utility of risk-based survivorship care plans to address the negative, additive impact of comorbidities and the treatment-related symptoms to improve the health-related QOL among rural survivors. Future research should assess how contextual factors (e.g., geographic distance to oncologists and other providers) should be incorporated in survivorship care planning and implementation for rural survivors.
Literature
1.
2.
Weaver KE, Palmer N, Lu L, Case LD, Geiger AM (2013) Rural–urban differences in health behaviors and implications for health status among US cancer survivors. Cancer Causes Control 24:1481–1490PubMedPubMedCentralCrossRef
3.
Burris JL, Andrykowski M (2010) Disparities in mental health between rural and nonrural cancer survivors: a preliminary study. Psycho-Onology 19:637–645CrossRef
4.
Gunn KM, Berry NM, Meng X, Wilson CJ, Dollman J, Woodman RJ, Clark RA, Koczwara B (2019) Differences in the health, mental health and health-promoting behaviours of rural versus urban cancer survivors in Australia. Support Care Cancer:1–11
5.
DiSipio T, Hayes SC, Newman B, Aitken J, Janda M (2010) Does quality of life among breast cancer survivors one year after diagnosis differ depending on urban and non-urban residence? A comparative study. Health Qual Life Outcomes 8:3PubMedPubMedCentralCrossRef
6.
Lashbrook M, Bernardes CM, Kirshbaum MN, Valery PC (2019) Physical functioning and psychological morbidity among regional and rural cancer survivors: a report from a regional cancer centre. Aust J Rural Health 26(3):211–219CrossRef
7.
O’Connor A, Wellenius G (2012) Rural–urban disparities in the prevalence of diabetes and coronary heart disease. Public Health 126:813–820PubMedCrossRef
8.
9.
Blake KD, Moss JL, Gaysynsky A, Srinivasan S, Croyle RT (2017) Making the case for investment in rural cancer control: an analysis of rural cancer incidence, mortality, and funding trends. Cancer Epidemiol Prev Biomarkers 26:992–997CrossRef
10.
Palmer NR, Geiger AM, Lu L, Case LD, Weaver KE (2013) Impact of rural residence on forgoing healthcare after cancer because of cost. Cancer Epidemiol Prev Biomarkers 22:1668–1676CrossRef
11.
Baldwin L, Cai Y, Larson EH, Dobie SA, Wright GE, Goodman DC, Matthews B, Hart LG (2008) Access to cancer services for rural colorectal cancer patients. J Rural Health 24:390–399PubMedPubMedCentralCrossRef
12.
Franceschini J, dos SAA, El Mouallem I, Jamnik S, Uehara C, Fernandes ALG, Santoro IL (2008) Assessment of the quality of life of patients with lung cancer using the Medical Outcomes Study 36-item Short-Form Health Survey. J Bras Pneumol 34:387–393PubMedCrossRef
13.
Ferrans CE, Zerwic JJ, Wilbur JE, Larson JL (2005) Conceptual model of health-related quality of life. J Nurs Scholarsh 37:336–342PubMedCrossRef
14.
Beck SL, Towsley GL, Caserta MS, Lindau K, Dudley WN (2009) Symptom experiences and quality of life of rural and urban older adult cancer survivors. Cancer Nurs 32:359–369PubMedCrossRef
15.
Chabowski M, Polański J, Mazur G, Janczak D, Rosińczuk J (2017) Sociodemographic and clinical determinants of quality of life of patients with non-small cell lung cancer. In: Clinical management of pulmonary disorders and diseases. Springer, Berlin, pp 1–10
16.
Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR (2008) Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol 26:971CrossRef
17.
Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS (2003) Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 97:2919–2925PubMedCrossRef
18.
Gerend MA, Pai M (2008) Social determinants of Black-White disparities in breast cancer mortality: a review. Cancer Epidemiol Prev Biomarkers 17:2913–2923CrossRef
19.
Beesley V, Eakin E, Steginga S, Aitken J, Dunn J, Battistutta D (2008) Unmet needs of gynaecological cancer survivors: implications for developing community support services. Psycho-Oncology 17:392–400PubMedCrossRef
20.
Pedro L (2012) Theory derivation: adaptation of a contextual model of health related quality of life to rural cancer survivors. Online J Rural Nurs Health Care 10:80–95CrossRef
21.
Naughton MJ, Weaver KE (2014) Physical and mental health among cancer survivors considerations for long-term care and quality of life. N C Med J 75:283–286PubMedPubMedCentral
22.
23.
Andrykowski MA (2012) Physical and mental health status of survivors of multiple cancer diagnoses: findings from the national health interview survey. Cancer 118:3645–3653PubMedCrossRef
24.
Russell L, Gough K, Drosdowsky A, Schofield P, Aranda S, Butow PN, Westwood JA, Krishnasamy M, Young JM, Phipps-Nelson J (2015) Psychological distress, quality of life, symptoms and unmet needs of colorectal cancer survivors near the end of treatment. J Cancer Surviv 9:462–470PubMedCrossRef
25.
Sehl M, Lu X, Silliman R, Ganz PA (2013) Decline in physical functioning in first 2 years after breast cancer diagnosis predicts 10-year survival in older women. J Cancer Surviv 7:20–31PubMedCrossRef
26.
Deimling GT, Arendt JA, Kypriotakis G, Bowman KF (2009) Functioning of older, long-term cancer survivors: the role of cancer and comorbidities. J Am Geriatr Soc 57:S289–S292PubMedCrossRef
27.
28.
Yabroff KR, Dowling E, Rodriguez J, Ekwueme DU, Meissner H, Soni A, Lerro C, Willis G, Forsythe LP, Borowski L (2012) The Medical Expenditure Panel Survey (MEPS) experiences with cancer survivorship supplement. J Cancer Surviv 6:407–419PubMedPubMedCentralCrossRef
29.
Centers for Disease Control and Prevention (CDC) (2013) About the Behavioral Risk Factor Surveillance System (BRFSS).(2016)
30.
Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Care Res 49:156–163CrossRef
31.
Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30:1326–1336CrossRef
32.
Yost KJ, Thompson CA, Eton DT, Allmer C, Ehlers SL, Habermann TM, Shanafelt TD, Maurer MJ, Slager SL, Link BK (2013) The Functional Assessment of Cancer Therapy-General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leuk Lymphoma 54:290–297PubMedCrossRef
33.
Fairclough D, Cella D (1996) Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions. Qual Life Res 5:321–329PubMedCrossRef
34.
Ware JE Jr, Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220–233PubMedCrossRef
35.
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMedCrossRef
36.
Brucker PS, Yost K, Cashy J, Webster K, Cella D (2005) General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 28:192–211PubMedCrossRef
37.
SPSS I (2013) SPSS statistics for Windows. IBM, Corp, Armonk, NY
38.
Ciucă A, Băban A (2017) Psychological factors and psychosocial interventions for cancer related pain. Rom J Intern Med 55:63–68PubMed
39.
Slavich GM, Auerbach RP (2018) Stress and its sequelae: depression, suicide, inflammation, and physical illness. In: APA handbook of psychopathology: psychopathology: understanding, assessing, and treating adult mental disorders 1:0000064–016
40.
Tate DG, Forchheimer M (2002) Quality of life, life satisfaction, and spirituality: comparing outcomes between rehabilitation and cancer patients. Am J Phys Med Rehabil 81:400–410PubMedCrossRef
41.
Mehnert A, Koch U (2008) Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. J Psychosom Res 64:383–391PubMedCrossRef
42.
Hewitt M, Greenfield S, Stovall E (2005) From cancer patient to cancer survivor: lost in transition. National Academies Press, Washington, D.C
43.
Given CW, Given B, Azzouz F, Kozachik S, Stommel M (2001) Predictors of pain and fatigue in the year following diagnosis among elderly cancer patients. J Pain Symptom Manag 21:456–466CrossRef
44.
Mayer DK, Birken SA, Check DK, Chen RC (2015) Summing it up: an integrative review of studies of cancer survivorship care plans (2006–2013). Cancer 121:978–996PubMedCrossRef
45.
McCabe MS, Bhatia S, Oeffinger KC, Reaman GH, Tyne C, Wollins DS, Hudson MM (2013) American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol 31:631PubMedPubMedCentralCrossRef
46.
Mayer DK, Alfano CM (2019) Personalized risk-stratified cancer follow-up care: its potential for healthier survivors, happier clinicians, and lower costs. J Natl Cancer Inst 111:442–448PubMedPubMedCentralCrossRef
47.
Alfano CM, Leach CR, Smith TG, Miller KD, Alcaraz KI, Cannady RS, Wender RC, Brawley OW (2019) Equitably improving outcomes for cancer survivors and supporting caregivers: a blueprint for care delivery, research, education, and policy. CA Cancer J Clin 69:35–49PubMedCrossRef
48.
Halpern MT, McCabe MS, Burg MA (2016) The cancer survivorship journey: models of care, disparities, barriers, and future directions. Am Soc Clin Oncol Educ Book 36:231–239CrossRef
49.
Schootman M, Homan S, Weaver KE, Jeffe DB, Yun S (2013) Peer reviewed: the health and welfare of rural and urban cancer survivors in Missouri. Prev Chronic Dis 10:1–11CrossRef
50.
McCabe MS, Partridge AH, Grunfeld E, Hudson MM (2013) Risk-based health care, the cancer survivor, the oncologist, and the primary care physician. Semin Oncol 40:804–812PubMedPubMedCentralCrossRef
51.
Loonen J, Blijlevens NM, Prins J, Dona DJ, Den Hartogh J, Senden T, van Dulmen-Den Broeder E, van der Velden K, Hermens RP (2018) Cancer survivorship care: person centered care in a multidisciplinary shared care model. Int J Integr Care 1–18
Metadata
Title
Comorbidities, treatment-related consequences, and health-related quality of life among rural cancer survivors
Authors
Shaila M. Strayhorn
Leslie R. Carnahan
Kristine Zimmermann
Theresa A. Hastert
Karriem S. Watson
Carol Estwing Ferrans
Yamilé Molina
Publication date
01-04-2020
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 4/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-05005-7

Other articles of this Issue 4/2020

Supportive Care in Cancer 4/2020 Go to the issue

Letter to the Editor

Prognostication, palliative care, and patient outcomes (reply to Rossi et al.)

Original Article

Municipality-based pragmatic rehabilitation stratified in accordance with individual needs—results from a longitudinal survey study

Original Article

Oral cryotherapy for oral mucositis management in patients receiving allogeneic hematopoietic stem cell transplantation: a prospective randomized study

Review Article

A systematic review and meta-analysis of couple-based intervention on sexuality and the quality of life of cancer patients and their partners

Letter to the Editor

Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer

Original Article

Clinical and sociodemographic factors that affect the quality of life of survivors of head and neck cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits